drugset / Trial / NCT00154401

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

NCT00154401

Phase 2 Completed 177 enrolled Novo Nordisk A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is conducted in Europe. The trial is designed to show the effect of treatment with liraglutide or placebo on blood glucose control after 14 weeks in subjects with type 2 diabetes. Liraglutide or placebo is administered by injection once daily in the evening. The trial is a multi-national trial with treatment concealed to participating subjects, investigators and the sponsor. Treatment allocation is random with equal chance of being assigned to each group.

Timeline

Start
2005-01
Primary completion
2005-10
Completion
2005-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide 0.65 mg Other
Subject Liraglutide Peptide 1.25 mg Other
Subject Liraglutide Peptide 1.9 mg Other